ArticleJACC. Case reports2026
Renal Denervation in Severe Neurogenic Dysautonomia: The RANSOM Prospective Experience.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere neurogenic dysautonomia in advanced neurodegenerative disorders is characterized by extreme blood pressure variability, orthostatic instability, and recurrent syncopal events. Therapeutic options are limited, and these patients are commonly excluded from conventional hypertension trials. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: We report the first prospective, single-center experience of renal sympathetic denervation in 12 patients with advanced parkinsonian syndromes and severe autonomic dysfunction with marked blood pressure variability. All procedures were successfully performed using a multielectrode radiofrequency catheter without complications. At 6-month follow-up, mean blood pressure values did not significantly change. Nevertheless, 9 patients were classified as responders, 1 as a partial responder, 1 as a nonresponder, and 1 had incomplete 6-month follow-up, based on a pragmatic multidisciplinary clinical assessment integrating syncopal burden, orthostatic tolerance, and patient-reported symptomatic benefit. DISCUSSION: Renal denervation was feasible and safe in this frail population. Because the study was small, uncontrolled, and lacked systematic autonomic testing at follow-up, efficacy findings should be considered exploratory and hypothesis-generating. NOVELTY: To the best of our knowledge, this is the first reported prospective experience of renal sympathetic denervation in severe neurogenic sympathetic dysautonomia. TAKE-HOME MESSAGE: Renal sympathetic modulation may represent a therapeutic option in selected patients with disabling autonomic dysfunction, but controlled studies with objective autonomic assessments are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.